A Double-blind, Placebo Controlled First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intra-articular Doses of SAR446959, in Participants With Osteoarthritis of the Knee
Latest Information Update: 26 Sep 2025
At a glance
- Drugs SAR 446959 (Primary) ; Gadoterate-meglumine
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Sanofi
Most Recent Events
- 15 Aug 2025 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2025 Planned End Date changed from 25 Dec 2025 to 19 Dec 2025.
- 15 Aug 2025 Planned primary completion date changed from 16 Dec 2025 to 19 Dec 2025.